Crizotinib proves to be effective against nonsmall-cell lung cancer (NSCLC) with ROS-1 translocations and has modest activity in c-MET >6 copies and c-MET mutations, according to the results of the phase II AcSé trial.
An association exists between cribriform pattern with intraductal carcinoma and adverse outcomes in men with Gleason 7 prostate cancer treated with external beam radiotherapy, reports a study. Cribriform pattern without intraductal carcinoma shows no association.
The phase II AMN001* trial conducted by the Asian Myeloma Network confirmed the efficacy of a pomalidomide plus dexamethasone regimen in Asian patients with relapsed/refractory multiple myeloma (RRMM), with a potential added benefit following the addition of cyclophosphamide.
Concurrent chemoradiotherapy (CCRT) appeared to improve survival rates in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), according to a systematic review and meta-analysis, with a potential benefit noted with the addition of induction chemotherapy.
Despite the known effectiveness of various interventional oncology (IO) procedures in many areas of cancer treatment, many continue to be overlooked in treatment guidelines due to evidence issues, say experts.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.
Intraoperative epidural analgesia, perioperative opioid and total dose of volatile agent appear to show some “clinically meaningful associations” with relapse-free survival (RFS) in children with solid organ tumour, particularly in paediatric sarcoma patients, according to a Singapore study. However, no statistically significant association exists between epidural use and an improved RFS.
The triplet regimen of encorafenib, binimetinib and cetuximab provides significant and clinically relevant benefits in overall survival (OS) and objective response rate (ORR) in patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who experience disease progression after one or two previous regimens, according to results of an interim analysis of the BEACON CRC trial.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.